{
  "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe",
  "docSlug": "303c45082bb692ab214f73eda43168dc",
  "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides",
  "authorId": "neurobo-pharmaceuticals",
  "authorName": "NeuroBo Pharmaceuticals",
  "documentKindSlug": "regulatory-filing",
  "documentKindLabel": "Regulatory filing",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 30,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Includes a bar chart for NASH diagnosis and a funnel diagram for Obesity patient progression.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/22",
  "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe",
  "deckJsonHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe.json",
  "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.1,
        "y": 0.4
      },
      "kind": "chart",
      "text": "Projected Diagnosed Prevalence in 2032",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e083f22-e493-492f-b336-41d8a76ab4a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.35,
        "x": 0.55,
        "y": 0.4
      },
      "kind": "chart",
      "text": "4.7M Treated Obesity Patients, 2029",
      "attrs": null,
      "subkind": "funnel",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae512025-2246-46c3-bbd7-95b9dbb60942",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.4,
        "x": 0.53,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "It is estimated ~40% of patients on pharmacotherapy will receive a GLP-1 based therapy like semaglutide or tirzepatide. Of those, 20% to 25% will progress to GLP1/GCGR dual agonists due to lack of response or issues with tolerance",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3463f79a-08dc-4d4b-ac41-988716fc9ab0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.1,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "NASH diagnosis rates will increase upon the approval of new pipeline therapies in the coming years, reaching a peak of 50% by 2032",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "878dc8ba-d11f-48f3-b46d-c1e444113282",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Source: Health Advances Quantitative Research",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f547e88-3c63-4f00-9279-b7b25aaa021d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.02,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Notes: GLP1R/GCGR (Glucagon-Like Peptide 1 Receptor/ Glucagon Receptor); NASH (Non-Alcoholic Steatohepatitis);",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "333a71a0-542d-45cc-a65b-948547f9b11d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.05,
        "y": 0.04
      },
      "kind": "title",
      "text": "Developing Assets Targeting Significant Opportunities of Unmet Need...",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06262a04-4f9c-4241-bb53-38305455e41f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "market-sizing",
      "slug": null,
      "matchId": "adbbb753-49fd-45e8-b2e9-286a3d780d3a",
      "evidence": "Quantification of patient populations for NASH and Obesity",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 22,
      "from": 22,
      "beatId": "0b489985-a547-4b6b-9a50-ab19a3e93367",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The document identifies a significant unmet need in NASH and T2DM",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 22,
      "from": 22,
      "beatId": "3108622d-a3c1-4546-b637-5070d586c3e8",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The document provides an overview of the market opportunity",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 22,
      "from": 22,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "7510a2ac-079c-414c-b25b-14aaafef2619",
      "evidence": "The document highlights the significant unmet need in NASH and T2DM",
      "position": 0,
      "objective": "What is the cost of not addressing NASH and T2DM?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}